Ocata Therapeutics Inc (NASDAQ:OCAT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Sunday, MarketBeat.com reports. According to Zacks, “Ocata Therapeutics, Inc. is a clinical stage biotechnology company. It is focused on the development and commercialization of regenerative ophthalmology therapeutics. Ocata focuses […]
